Kayoko Kibata

897 total citations
24 papers, 616 citations indexed

About

Kayoko Kibata is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Kayoko Kibata has authored 24 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Immunology. Recurrent topics in Kayoko Kibata's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Immune Cell Function and Interaction (4 papers). Kayoko Kibata is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (6 papers) and Immune Cell Function and Interaction (4 papers). Kayoko Kibata collaborates with scholars based in Japan. Kayoko Kibata's co-authors include Shosaku� Nomura, Toshiki Shimizu, Takeshi Tamaki, Tomoki� Ito, Takayasu Kurata, Makoto Ogata, Maiko Niki, Hiroshige Yoshioka, Akihiro Tanaka and Aya Nakaya and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and European Journal of Immunology.

In The Last Decade

Kayoko Kibata

23 papers receiving 611 citations

Peers

Countries citing papers authored by Kayoko Kibata

Since Specialization

Citations

This map shows the geographic impact of Kayoko Kibata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kayoko Kibata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kayoko Kibata more than expected).

Fields of papers citing papers by Kayoko Kibata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kayoko Kibata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kayoko Kibata. The network helps show where Kayoko Kibata may publish in the future.

Co-authorship network of co-authors of Kayoko Kibata

This figure shows the co-authorship network connecting the top 25 collaborators of Kayoko Kibata. A scholar is included among the top collaborators of Kayoko Kibata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kayoko Kibata. Kayoko Kibata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study 2024 ·Lung Cancer ·Akito Hata, Nobuyuki Katakami, (unknown), Kayoko Kibata, (unknown), Motohiro Tamiya, Masahide Mori, Takashi Kijima, Satoshi Morita, Kazuko Sakai, Kazuto Nishio	2
2	Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial 2023 ·BMC Cancer ·Satoru Miura, Yasuhiro Koh, Koichi Azuma, Hiroshige Yoshioka, K. Koyama, Shunsuke Teraoka, Hidenobu Ishii, Kayoko Kibata, Yuichi Ozawa, Takaaki Tokito, Jun Oyanagi, Toshio Shimokawa, Takayasu Kurata, Nobuyuki Yamamoto, Hiroshi Tanaka	5
3	Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer 2022 ·BMC Cancer ·Toshihiko Kaneda, Takayasu Kurata, Tomoko Yoshida, Kayoko Kibata, Hiroshige Yoshioka, Hiroaki Yanagimoto, Kazuhiko Takeda, Takao Yoshida, Koji Tsuta	2
4	SMARCA4‐deficient undifferentiated tumor that responded to chemotherapy in combination with immune checkpoint inhibitors: A case report 2022 ·Thoracic Cancer ·(unknown), Yohei Taniguchi, (unknown), (unknown), Kayoko Kibata, Tomohiro Murakawa	13
5	Emergent salvage surgery for massive hemoptysis after proton beam therapy for lung cancer: a case report 2021 ·SHILAP Revista de lepidopterología ·Haruaki Hino, (unknown), Makoto Ogata, Kayoko Kibata, (unknown), (unknown), (unknown), Hiroshi Matsui, Yohei Taniguchi, Tomohito Saito, Koji Tsuta, Tomohiro Murakawa	1
6	<p>The immunomodulatory-drug, lenalidomide, sustains and enhances interferon-α production by human plasmacytoid dendritic cells</p> 2019 ·Journal of Blood Medicine ·Kayoko Kibata, Tomoki� Ito, Muneo Inaba, Akihiro Tanaka, (unknown), (unknown), (unknown), Atsushi� Satake, Shosaku� Nomura	8
7	Statins can suppress DC‐mediated Th2 responses through the repression of OX40‐ligand and CCL17 expression 2019 ·European Journal of Immunology ·(unknown), Tomoki� Ito, Muneo Inaba, (unknown), Akihiro Tanaka, (unknown), Kayoko Kibata, Atsushi� Satake, Shosaku� Nomura	14
8	Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer 2018 ·Oncotarget ·Maiko Niki, Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Toshihiko Kaneda, Kayoko Kibata, Makoto Ogata, Shosaku� Nomura	63
9	Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab 2018 ·International Journal of Clinical Oncology ·Aya Nakaya, Takayasu Kurata, Hiroshige Yoshioka, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, (unknown), Makoto Ogata, Takayuki Miyara, Shosaku� Nomura	94
10	Lenalidomide Acts As a Positive Immunomodulator through Modulating the Functions of Human Plasmacytoid Dendritic Cells 2017 ·Blood ·Tomoki� Ito, Kayoko Kibata, Muneo Inaba, (unknown), (unknown), Hideaki� Yoshimura, Masaaki� Hotta, Takahisa� Nakanishi, Shinya� Fujita, Aya Nakaya, Atsushi� Satake, Kazuyoshi� Ishii, Shosaku� Nomura	0
11	Interstitial Lung Disease Following Single-Agent Nanoparticle Albumin-Bound Paclitaxel Treatment in Patients with Advanced Non-Small Cell Lung Cancer 2017 ·Case Reports in Oncology ·Yuki Nakatani, Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, (unknown), Makoto Ogata, Takayuki Miyara, Shosaku� Nomura	2
12	Retrospective analysis of single-agent nab-paclitaxel in patients with platinum-resistant non-small cell lung cancer 2017 ·Molecular and Clinical Oncology ·Aya Nakaya, Takayasu Kurata, Takashi Yokoi, Yuki Takeyasu, Maiko Niki, Kayoko Kibata, (unknown), Yoshitaro Torii, (unknown), Makoto Ogata, Takayuki Miyara, Shosaku� Nomura	7
13	Phase I/II study of erlotinib, carboplatin, pemetrexed, and bevacizumab in chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer harboring epidermal growth factor receptor mutation 2017 ·Genes & Cancer ·Takayasu Kurata, Aya Nakaya, Takashi Yokoi, Maiko Niki, Kayoko Kibata, Yuki Takeyasu, Yoshitaro Torii, (unknown), Makoto Ogata, Takayuki Miyara, Shosaku� Nomura	5
14	Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer 2014 ·Oncology Letters ·Takashi Yokoi, Yoshitaro Torii, (unknown), Hiroyuki Sugimoto, (unknown), Makoto Ogata, (unknown), Kayoko Kibata, (unknown), Maiko Niki, Toshiki Shimizu, Takayuki Miyara, Takayasu Kurata, Shosaku� Nomura	9
15	IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand 2014 ·Allergology International ·(unknown), Tomoki� Ito, Takahisa� Nakanishi, (unknown), Akihiro Tanaka, (unknown), Kayoko Kibata, Muneo Inaba, Shosaku� Nomura	98
16	Platelet-derived RANK ligand enhances CCL17 secretion from dendritic cells mediated by thymic stromal lymphopoietin 2014 ·Platelets ·Takahisa� Nakanishi, Muneo Inaba, (unknown), Akihiro Tanaka, (unknown), Kayoko Kibata, Tomoki� Ito, Shosaku� Nomura	17
17	Primary intrahepatic malignant mesothelioma with multiple lymphadenopathies due to non-tuberculous mycobacteria: A case report and review of the literature 2013 ·Oncology Letters ·(unknown), Kayoko Kibata, Takeshi Tamaki, Toshiki Shimizu, Shosaku� Nomura	15
18	Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer 2013 ·Lung Cancer ·(unknown), Kayoko Kibata, Takeshi Tamaki, Toshiki Shimizu, Shosaku� Nomura	114
19	Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer 2013 ·Oncology Letters ·Toshiki Shimizu, Takashi Yokoi, Takeshi Tamaki, Kayoko Kibata, (unknown), Shosaku� Nomura	7
20	Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy 2013 ·Oncology Letters ·Kayoko Kibata, Takeshi Tamaki, (unknown), Makoto Ogata, Toshiki Shimizu, Shosaku� Nomura	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact